Pancreatic Cancer within a UK Cancer Network with Special Emphasis on Locally Advanced Non-metastatic Pancreatic Cancer
- 30 September 2008
- journal article
- Published by Elsevier BV in Clinical Oncology
- Vol. 20 (7), 535-540
- https://doi.org/10.1016/j.clon.2008.02.003
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJournal of Clinical Oncology, 2007
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III TrialJournal of Clinical Oncology, 2005
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancerInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcomeInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic CancerJournal of Clinical Oncology, 2004
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreasJournal of Gastrointestinal Surgery, 2003
- Surgical Resection After Preoperative Chemoradiotherapy Benefits Selected Patients With Unresectable Pancreatic CancerAmerican Journal of Clinical Oncology, 2003
- A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBritish Journal of Cancer, 2002